2McConnell JD, Roehrborn CG, Bautista OM, et al. The long- term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia [J].N Engl J Med, 2003, 349(25) :2387-2398.
3Russell DW, Wilson JD. Steroid 5 alpha-reductase:two genes/two enzymes [J]. Annu Rev Biochem, 1994, 63:25-61.
4Chen W, Zouboulis CC, Fritsch M, et al. Evidence of heterogeneity and quantitative differences of the type 1 5alpha-reductase expression in cultured human skin cells-evidence of its presence in melanocytes [J]. J Invest Dermatol, 1998, 110(1):84-89.
5Yokoi H, Tsuruo Y, Miyamoto T, et al. Steroid 5 alpha-reductase type 1 immunolocalized in the adrenal gland of normal, gonadectomized, and sex hormone-supplemented rats [J]. Histochem Cell Biol, 1998, 109(2):127-134.
6PC Walsh, AB Reyik. Treatment of BPH [J]. Campbell Urology, 1998, 7:1337-1378.
8Hudson PB, Boake R, Trachtenberg J, et al. Efficacy of finasteride is maintained in patients with benign prostatic hyperplasia treated for 5 years. The North American Finasteride Study Group [J]. Urology, 1999, 53(4) :690-695.
9Sun ZY, Wu HY, Wang MY, et al. The mechanism of epristeride against benign prostatic hyperplasia [J]. Eur J Pharmacol, 1999, 371(2-3) :227-233.
10Wu SF, Sun HZ, Qi XD, et al. Effect of epristeride on the expression of IGF-1 and TGF-beta receptors in androgen-induced castrated rat prostate [J]. Exp Biol Med (Maywood), 2001,226(10) :954-960.
4[1]Audet. PH., Lamb Y, Jorkasky D, et al. Effect of multiple doses of epristends, a steroid 5a- reductase inhibitor, on serum dihydrotestos- terone in older male subjects. Clin Pharmacol Ther, 1993; 53: 231.
5[2]Johnsonbaugh RE, Cohen BR, McCormack, EM, et al. Effect of fourteen days treatment with epristeride, an uncompetitive 5a- reductase inhibitor. on serum and prostatic testosterone and dihydrotestosterone in men with benign prostatic hyperpiasia. J Urol, 1993; 149: 423a.
6[3]Depre M, Meeter C, Hecken AV, et al. Pharmacodynamics and tolerability of L-654,066, a steroid 5a- reductase inhibitor, in men. Clin Pharmacol Ther, 1992; 52: 409～412.
7[4]Boppana VB, et al. Normal - phase high performance liquid chromto- graphic determination of epristeride, a prestatic steroid 5a- reductase enzyme inhibitor, inhuman plasma. J Chromatogr, 1993; 631: 251～254.
